Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 13/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9887964 | 0.79 | PNP (0.60) | PNP | |
| SCHEMBL15628196 | 0.78 | PDPK1 (0.55) | PNPALDH1A1PARP1PDPK1 | |
| SCHEMBL2429951 | 0.78 | PNP (0.49) | PNPALDH1A1PDPK1 | |
| SCHEMBL13691975 | 0.76 | PNP (0.62) | PNP | |
| SCHEMBL14087021 | 0.75 | PNP (0.46) | PNPALDH1A1PDPK1 | |
| SCHEMBL29951398 | 0.75 | PNP (0.48) | PNPALDH1A1PDPK1 | |
| SCHEMBL12715779 | 0.73 | PDPK1 (0.53) | PNPALDH1A1PDPK1 | |
| SCHEMBL22907451 | 0.73 | PNP (0.55) | PNPALDH1A1PDPK1 | |
| SCHEMBL3945500 | 0.73 | PNP (0.45) | PNPALDH1A1PDPK1 | |
| SCHEMBL22399745 | 0.72 | PDPK1 (0.49) | PNPALDH1A1PARP1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173662-B2 | Fused pyrimidines as inhibitors of nucleoside phosphorylases and nucleosidases | INDUSTRIAL RESEARCH LIMITED (NZ) | 2012-05-08 | — | — | US | disclosed |
| US-8173662-B2 | Fused pyrimidines as inhibitors of nucleoside phosphorylases and nucleosidases | INDUSTRIAL RESEARCH LIMITED (NZ) | 2012-05-08 | — | — | US | disclosed |
| US-20090239885-A1 | Inhibitors of nucleoside phoshorylases and nucleosidases | BIOCRYST PHARMACEUTICALS, INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090239885-A1 | Inhibitors of nucleoside phoshorylases and nucleosidases | BIOCRYST PHARMACEUTICALS, INC. | 2009-09-24 | — | — | US | disclosed |
| US-7553839-B2 | 5h-pyrrolo[3,2-D] pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases | INDUSTRIAL RESEARCH LIMITED (NZ) | 2009-06-30 | — | — | US | disclosed |
| US-7553839-B2 | 5h-pyrrolo[3,2-D] pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases | INDUSTRIAL RESEARCH LIMITED (NZ) | 2009-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239885-A1 | Inhibitors of nucleoside phoshorylases and nucleosidases | PNP, MTAP, TYMP | PNP 1/4885ALDH1A1 2578/4885PARP1 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.